Pfizer's Talzenna Approved for Earlier Use in Prostate Cancer Following Phase 3 Trial Success on March 19, 2026 enzalutamide HRR gene mutation mCRPC Metastatic castration-resistant prostate cancer Pfizer Poly(ADP-ribose) Polymerase Inhibitors TALAPRO-2 talazoparib Talzenna Xtandi +
MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene on November 14, 2025 Adagene Antibodies, Bispecific Arc Bio CD3 T cell Clinical Trials engagers licensing agreement lorigerlimab MacroGenics mCRPC SAFEbody technology +
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer's Prostate Cancer Drug Combo on May 22, 2025 Advisory Committees enzalutamide expansion Inhibitor Labels (device) Malignant neoplasm of prostate mCRPC PARP1 gene Pfizer talazoparib Talzenna unanimous vote United States Food and Drug Administration +
Lava cuts jobs by 30% after key drug discontinued on February 27, 2025 cash runway Discontinuation (procedure) LAVA LAVA-1266 mCRPC restructuring strategic alternatives +